MicroRNAs as a New Molecular Biomarker for Diagnosis and Prognosis of T-cell Acute Lymphoblastic Leukemia (T-ALL): A Systematic Review
Authors
Abstract:
MicroRNAs (miRNAs, miRs) are small endogenous non-coding RNAs that regulate the expression of protein-encoding genes at the post-transcriptional level. Several studies have described the role of miRNAs in T-cell acute lymphoblastic leukemia (T-ALL), including tumor suppressor and oncogenic miRNAs. Down-regulation of miRNA expression is a prominent feature of human malignancy. This down-regulation can be triggered by certain chromosomal rearrangements, such as somatic deletions or translocations. New functional studies showed that dysregulation of microRNAs plays significant roles in cellular proliferation, differentiation, apoptosis, in human cancers such as leukemia. In this review, we focused on the major recent findings in the microRNA signatures in ALL pathogenesis and we discussed the potential use of cellular and circulating miRNAs as new molecular biomarkers for diagnosis and prognosis of acute lymphoblastic leukemia. In this systematic review article, 76 articles were collected from 2004 to February 2019. We chose research and review articles from open access journals which include MeSH terms such as ALL, T-ALL, microRNA, oncogenic miRNA, Tumor Suppressor miRNA, microRNA Expression and signaling pathway. Investigation of data showed that alterations in oncogenic and tumor suppressor miRNAs expression changed the expression of genes related to accurate cell functions and consequently the pathogenicity of T-ALL.
similar resources
DETERMINATION OF A SHARED EPITOPE ON CELLS FROM ACUTE MYELOGENIC LEUKEMIA (AML) AND T-ACUTE LYMPHOBLASTIC LEUKEMIA ( T-ALL)
Two IgM monoclonal antibodies (MAb) with strong reactivity for granulocytes and to a lesser extent for lurkat cell lines were established by immunizing BALBI c mice with a histiocytic cell line (UY37). These two MAbs (designated as 6C9 and 4C4) reacted with blast cells of T-acute lymphoblastic leukemia (T-ALL) and acute myelogenous leukemia (AML) patients as well as leukemic cells from pat...
full textdetermination of a shared epitope on cells from acute myelogenic leukemia (aml) and t-acute lymphoblastic leukemia ( t-all)
two igm monoclonal antibodies (mab) with strong reactivity for granulocytes and to a lesser extent for lurkat cell lines were established by immunizing balbi c mice with a histiocytic cell line (uy37). these two mabs (designated as 6c9 and 4c4) reacted with blast cells of t-acute lymphoblastic leukemia (t-all) and acute myelogenous leukemia (aml) patients as well as leukemic cells from patients...
full textProlonged Vincristine Toxicity Induced by Concurrent Posaconazole in a Child with T-cell Acute Lymphoblastic Leukemia
full text
Proteasome Inhibition by Carfilzomib Induced Apotosis and Autophagy in a T-cell Acute Lymphoblastic Leukemia Cell Line
T-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy which is usuallyassociated with unfavorable prognosis particularly in patients with refractory/relapsed disease.Therefore, development of novel therapeutic strategies is highly required for improving theoutcome of these patients. Although there are several studies evaluating the efficacy of proteasome<...
full textmicroRNAs regulate TAL1 expression in T-cell acute lymphoblastic leukemia
The transcription factor TAL1 is a proto-oncogene whose aberrant expression in committed T-cell precursors is associated with the development of T-cell acute lymphoblastic leukemia (T-ALL). The mechanisms leading to aberrant activation of TAL1 in T-ALL patients who lack chromosomal rearrangements involving the TAL1 locus remain largely unknown. We hypothesized that TAL1 levels decrease during n...
full textProteasome Inhibition by Carfilzomib Induced Apotosis and Autophagy in a T-cell Acute Lymphoblastic Leukemia Cell Line
T-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy which is usuallyassociated with unfavorable prognosis particularly in patients with refractory/relapsed disease.Therefore, development of novel therapeutic strategies is highly required for improving theoutcome of these patients. Although there are several studies evaluating the efficacy of proteasome<...
full textMy Resources
Journal title
volume 10 issue 3
pages 184- 200
publication date 2020-07
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023